2.25
-0.035(-1.53%)
Currency In USD
| Previous Close | 2.29 |
| Open | 2.25 |
| Day High | 2.33 |
| Day Low | 2.16 |
| 52-Week High | 10.16 |
| 52-Week Low | 2.08 |
| Volume | 10,126 |
| Average Volume | 223,539 |
| Market Cap | 6.46M |
| PE | -1.47 |
| EPS | -1.53 |
| Moving Average 50 Days | 2.81 |
| Moving Average 200 Days | 3.68 |
| Change | -0.04 |
If you invested $1000 in Biomerica, Inc. (BMRA) 10 years ago, it would be worth $338.86 as of November 19, 2025 at a share price of $2.25. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 5 years ago, it would be worth $43.74 as of November 19, 2025 at a share price of $2.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
GlobeNewswire Inc.
Nov 06, 2025 1:19 PM GMT
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BM
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
GlobeNewswire Inc.
Oct 16, 2025 12:19 PM GMT
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIR
Biomerica Reports First Quarter Fiscal 2026 Financial Results
GlobeNewswire Inc.
Oct 15, 2025 1:27 PM GMT
Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational Ef